Neulasta ™

Generic name: Pegfilgrastim
Other names: G-CSF, Granlocyte - Colony Stimulating Factor

Chemocare.com uses generic names in all descriptions of drugs. Neulasta is the trade name for Pegfilgrastim. G-CSF and Granlocyte - Colony Stimulating Factor are other names for Pegfilgrastim. In some cases, health care professionals may use the trade name Neulasta or other names G-CSF and Granlocyte - Colony Stimulating Factor when referring to the generic drug name Pegfilgrastim.

Drug type: Neulasta is a biologic response modifier. It is classified as a colony stimulating factor. (For more detail, see "How this drug works" section below).

What is this drug used for?

This medicine is used to stimulate the growth of "healthy" white blood cells in the bone marrow, once chemotherapy is given. White blood cells help the body to fight infection. This is not a chemotherapy drug.
This medication is usually given at least 24 hours after chemotherapy to stimulate the growth of new, healthy, white blood cells (WBC).
Pegfilgrastim is a longer acting form of filgrastim and the manufacturer recommends that it should not be given within 14 days prior to chemotherapy.
Pegfilgrastim is given as a single injection.

Note: If a drug has been approved for one use, physicians sometimes elect to use this same drug for other problems if they believe it might be helpful.

How this drug is given:

This medicine can be given as a shot underneath the skin (subcutaneous [SQ]), in pre-filled syringes. The dose of pegfilgrastim depends upon why you are receiving this drug.
The amount of this medication you will receive also depends on many other factors, including your height and weight, your general health or other health problems, and the type of cancer you have. Your doctor will determine your dose and schedule.

Side effects:
Important things to remember about the side effects of pegfilgrastim:

Most people do not experience all of the side effects listed.
Side effects are often predictable in terms of their onset and duration.
Side effects are almost always reversible and will go away after treatment is complete.
There are many options to help minimize or prevent side effects.
There is no relationship between the presence or severity of side effects and the effectiveness of the medication.
Pegfilgrastim is a support medication. The following list includes side effects attributed to pegfilgrastim. Other side effects experienced were attributed to the chemotherapy and/or the disease.

The following side effects are common (occurring in greater than 30%) for patients taking pegfilgrastim:

Note: There are no common side effects of pegfilgrastim

These side effects are less common side effects (occurring in about 10-29%) of patients receiving pegfilgrastim:

Pain (bone pain)
Blood test abnormalities (temporary elevation in lactate dehydrogenase)
These will return to normal once treatment is discontinued
Tenderness at the site of injection

Not all side effects are listed above. Some that are rare (occurring in less than 10% of patients) are not listed here. However, you should always inform your health care provider if you experience any unusual symptoms.

When to contact your doctor:

Contact your health care provider immediately, day or night, if you should experience any of the following symptoms:

Fever of 100.5º F (38º C), chills, sore throat (possible signs of infection)
Shortness of breath
Rapid heart beat
Bleeding that does not stop after a few minutes
Any new rashes on your skin

The following symptoms require medical attention, but are not emergency situations. Contact your health care provider within 24 hours of noticing any of the following:

Bone pain that does not go away despite taking recommended pain reliever

Always inform your health care provider if you experience any unusual symptoms.

Precautions:

Before starting pegfilgrastim treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.). Do not take aspirin, products containing aspirin unless your doctor specifically permits this.
The manufacturer recommends that the first dose of pegfilgrastim be given no sooner than 24 hours after chemotherapy. Your doctor will discontinue therapy with pegfilgrastim when your white blood cell count has reached acceptable levels.
Pegfilgrastim may be inadvisable if you have had a hypersensitivity (allergic) reaction to filgrastim, pegfilgrastim or E. coli-derived proteins.
Do not receive any kind of immunization or vaccination without your doctor's approval while taking pegfilgrastim.
Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category C (use in pregnancy only when benefit to the mother outweighs risk to the fetus).
For both men and women: Do not conceive a child (get pregnant) while taking pegfilgrastim. Barrier methods of contraception, such as condoms, are recommended. Discuss with your doctor when you may safely become pregnant or conceive a child after therapy.
Do not breast feed while taking this medication.
Pegfilgrastim should be used with caution in people taking lithium.

Self-care tips:

If you are performing your own subcutaneous self-injections, remove the syringe from the refrigerator 30 minutes prior to injection. This will reduce local stinging at the injection site.
You may experience bone or joint pain as a result of this medication. Ask your healthcare provider if you may take a mild pain medicine to relieve this. Acetominophen (Tylenol^®) may help.
Apply a warm compress if you have any pain, redness or swelling at the injection site, and notify your doctor.
You may be at risk of infection so try to avoid crowds or people with colds, and report fever or any other signs of infection immediately to your health care provider.
Wash your hands often.
Avoid contact sports or activities that could cause injury.
This medication causes little nausea. But if you should experience nausea, take anti-nausea medications as prescribed by your doctor, and eat small, frequent meals. Sucking on lozenges, and chewing gum may also help.
In general, drinking alcoholic beverages should be kept to a minimum or avoided completely. You should discuss this with your doctor.
Get plenty of rest.
Maintain good nutrition.
If you experience symptoms or side effects, be sure to discuss them with your health care team. They can prescribe medications and/or offer other suggestions that are effective in managing such problems.

Monitoring and testing:

You will be checked regularly by your doctor while you are taking pegfilgrastim to monitor side effects and check your response to therapy. Periodic blood work to monitor your complete blood count (CBC) as well as the function of other organs (such as your kidneys and liver) will also be ordered by your doctor.

How this drug works:

Colony-Stimulating Factors:
In the body's bone marrow (the soft, sponge-like material found inside bones) blood cells are produced. There are three major types of blood cells; white blood cells, which fight infection; red blood cells, which carry oxygen to and remove waste products from organs and tissues; and platelets, which enable the blood to clot. Cancer treatments such as chemotherapy and radiation therapy can effect these cells which put a person at risk for developing infections, anemia and bleeding problems. Colony-stimulating factors are substances that stimulate the production of blood cells and promote their ability to function. They do not directly affect tumors but through their role in stimulating blood cells they can be helpful as support of the persons immune system during cancer treatment.

Pegfilgrastim is a growth factor that stimulates the production, maturation and activation of neutrophils. Pegfilgrastim also stimulates the release of neutrophils (a type of white blood cell) from the bone marrow. In patients receiving chemotherapy, pegfilgrastim can accelerate the recovery of neutrophils, reducing the neutropenic phase (the time in which people are susceptible to infections). Pegfilgrastim is a long-acting version of filgrastim.

Pegfilgrastim is filgrastim with a substance called polyethylene glycol (PEG) attached to it. The attachment process is called pegylation, and is used to allow active substances (the filgrastim) to stay in the body longer before they are broken down and eliminated.

Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in this website is meant to be helpful and educational, but is not a substitute for medical advice.